Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Treatment with VXM01, an investigational vaccine, plus Bavencio demonstrated both safety and tolerability in patients with ...

贝伐珠单抗耐药不可避免。安罗替尼是一种靶向肿瘤血管生成和增殖信号的新型多靶点酪氨酸激酶抑制剂。近些年来的研究提示，安罗替尼可通过下调 RGC32 或抑制 TGFβ1 ...

Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and ...

2025年3月成都的这场学术盛会，折射出中国每年新增4.5万例神经内分泌肿瘤患者的诊疗困境。作为发病率年增长超8%的'隐形杀手'，这类肿瘤因异质性强、诊断滞后等特点，五年生存率长期徘徊在40%-60%之间。当AI诊断系统在肺癌领域准确率突破95%时，NEN的误诊率仍高达38%，这种反差暴露出精准诊疗体系的建构已刻不容缓。本次论坛汇聚的23个学科专家，正试图用跨界思维破解这一医学难题。

US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.

Exelixis, Inc. EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation ...

During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations ...